|
Today's Headlines
Patients who increased doses of opioid medicines to manage chronic pain were more likely to experience an increase in depression, according to a study published in the February issue of Pain. » Details
|
|
FDA approved panobinostat (Farydak, Novartis Pharmaceuticals) for the treatment of patients with multiple myeloma, which is attributed to 10,710 deaths in the United States annually. » More
|
Continuing Education
This month and next month pharmacists will be able to learn about the latest developments in diabetes treatment and management. Pharmacists can earn up to 4 hours of CPE credit with two monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.
The goal of this month's activity is to discuss new and emerging medications for the treatment of diabetes.
Read/print the article: Click here
Take the test: Click here to log in with the Session Code 15DT15-WKX27.
Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is
https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/
|
|
EDITOR'S PICK
The introduction of high-cost, high-use PCSK9 inhibitors (proprotein convertase subtilisin/kexin 9) enzyme inhibitors to treat high cholesterol, takes the industry step closer to a future where "healthcare costs break the bank," according to industry insiders. » Read more.
|
|
|
Like
Tweet
